News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
67,002 Results
Type
Article (4549)
Company Profile (21)
Press Release (62432)
Section
Business (20956)
Career Advice (122)
Deals (2550)
Drug Delivery (4)
Drug Development (7874)
Employer Resources (3)
FDA (1343)
Job Trends (1203)
News (32461)
Policy (2283)
Tag
Academia (487)
Alliances (7011)
Alzheimer's disease (151)
Approvals (1337)
Artificial intelligence (24)
Bankruptcy (16)
Best Places to Work (1017)
Biotechnology (15)
Breast cancer (19)
Cancer (210)
Career advice (109)
Cell therapy (16)
Clinical research (5463)
Collaboration (70)
COVID-19 (371)
C-suite (17)
Cystic fibrosis (8)
Data (149)
Diabetes (8)
Diagnostics (2595)
Drug discovery (16)
Earnings (5503)
Events (9111)
Executive appointments (27)
FDA (1389)
Featured Employer (8)
Funding (33)
Gene editing (7)
Gene therapy (20)
GLP-1 (48)
Government (424)
Healthcare (1815)
Infectious disease (383)
Inflammatory bowel disease (11)
Interviews (10)
IPO (1014)
Job creations (216)
Job search strategy (100)
Layoffs (14)
Legal (268)
Lung cancer (39)
Medical device (536)
Medtech (536)
Mergers & acquisitions (1547)
Metabolic disorders (23)
Neuroscience (174)
NextGen Class of 2024 (487)
Non-profit (428)
Northern California (165)
Obesity (15)
Opinion (15)
Parkinson's disease (10)
People (7314)
Phase I (2201)
Phase II (2583)
Phase III (1530)
Pipeline (62)
Postmarket research (116)
Preclinical (1631)
Press Release (18)
Prostate cancer (8)
Radiopharmaceuticals (46)
Rare diseases (15)
Real estate (476)
Regulatory (1723)
Research institute (598)
Resumes & cover letters (15)
Southern California (100)
Startups (477)
United States (1218)
Vaccines (22)
Date
Today (20)
Last 7 days (71)
Last 30 days (367)
Last 365 days (3881)
2024 (3543)
2023 (4546)
2022 (5850)
2021 (6006)
2020 (5524)
2019 (3862)
2018 (2923)
2017 (3576)
2016 (3599)
2015 (4241)
2014 (2958)
2013 (2482)
2012 (2641)
2011 (2803)
2010 (2347)
Location
Africa (63)
Arizona (13)
Asia (3478)
Australia (772)
California (326)
Canada (97)
China (39)
Colorado (8)
Connecticut (14)
Europe (10155)
Florida (48)
Illinois (28)
Indiana (14)
Japan (9)
Maryland (60)
Massachusetts (223)
Michigan (12)
Minnesota (32)
New Jersey (98)
New York (81)
North Carolina (58)
Northern California (165)
Ohio (16)
Pennsylvania (57)
South America (95)
Southern California (100)
Texas (50)
Utah (29)
Washington State (29)
67,002 Results for "gt molecular".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
GT Molecular Announces an Ultra-Sensitive RT-PCR Multiplex Panel for Eight Key KRAS G12-G13 Mutations
GT Molecular, Inc. is adding to its cancer molecular assay product line with a multi-target RT-PCR assay kit featuring robust quality control metrics and internal process controls.
June 13, 2024
·
2 min read
Press Releases
GT Biopharma Reports Third Quarter 2024 Financial Results
November 14, 2024
·
10 min read
GT Molecular Launches Multiplexed Assay Kit for Respiratory Pathogen Detection on the Roche Digital LightCycler® System
GT Molecular, Inc., a company providing ultrasensitive PCR assays for wastewater-based epidemiology testing, pathogen detection, and cancer research is pleased to announce an agreement with Roche to provide a highly multiplexed respiratory panel for wastewater surveillance on the new Roche Digital LightCycler® System.
September 19, 2023
·
2 min read
Business
GT Medical Technologies, Inc. Appoints Two Industry Medical Device Veterans to Key Leadership Positions
GT Medical Technologies, Inc. today announced two significant additions to its leadership team: Tom Moore as Chief Commercial Officer and Sandeep Yadav as Chief Financial Officer.
June 20, 2024
·
2 min read
Earnings
Biogen Tops Wall Street Expectations for Leqembi, Inks Molecular Glue Deal
Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with Neomorph to discover and develop molecular glue degraders.
October 30, 2024
·
2 min read
·
Heather McKenzie
Collaboration
Novartis Inks Potential $2.2B Molecular Glue Deal With Monte Rosa
The Swiss pharma is paying $150 million upfront to gain rights to Monte Rosa’s VAV1-targeting molecular glue degraders, led by a Phase I candidate which holds therapeutic promise for immune-mediated diseases.
October 28, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
October 8, 2024
·
9 min read
Deals
GT Medical Technologies, Inc. Completes Strategic Acquisition of Radioactive Seed Assets from Perspective Therapeutics, Inc.
GT Medical Technologies, Inc. (GT MedTech) announces the successful acquisition of Cesium-131 and related assets from Isoray Medical, a subsidiary of Perspective Therapeutics, Inc.
April 15, 2024
·
5 min read
Business
GT Medical Technologies, Inc. and Theragenics Corporation Forge Distribution Partnership for Cesium-131
GT Medical Technologies, Inc. today announced it has entered into a strategic distribution partnership with Theragenics Corporation® (Theragenics), a global leader in minimally invasive brachytherapy.
May 1, 2024
·
4 min read
Drug Development
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
GT Biopharma, Inc. today announced FDA clearance of its IND application for GTB-3650, allowing the company to proceed with a Phase 1 clinical trial, which is anticipated to start in second half of 2024.
June 27, 2024
·
5 min read
1 of 6,701
Next
